Regeneron: 3 Key Takeaways for Long-Term Investors

Regeneron reported Q3 2026 revenue of $5.1 billion with 36% year-over-year growth. Key drivers include Dupixent reaching record sales of $6.5 billion (up 35% YoY), EYLEA HD expanding rapidly with U.S. sales of $699 million (up 62%), and promising early-stage liver disease therapy showing 70% fat reduction in 12 weeks. The company plans to increase research spending by mid-teens percentage in 2027 to fund 15 late-stage clinical trials.